RxDoctor Payments Data

Hong Bui, MD

Internal Medicine · San Jose, CANPI 1417944471

Payments from drug & device makers

$809in general payments, 2019–2025

Across 8 payments — averaging $101.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$275
  • AstraZeneca$139
  • Silk Road Medical, Inc.$127
  • Boehringer Ingelheim$125
  • Sunovion Pharmaceuticals Inc.$125
  • Ascend Therapeutics US, LLC$18

What the payments were for

  • Food & beverage$79198%
  • Gifts$182%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Boston Scientific2$275
AstraZeneca2$139
Silk Road Medical, Inc.1$127
Boehringer Ingelheim1$125
Sunovion Pharmaceuticals Inc.1$125
Ascend Therapeutics US, LLC1$18

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$809 in reported general payments places this provider in the 70th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$151,730
Medicare patients
398
Services billed
1,420

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin222$180,911
JanuviaSitagliptin Phosphate151$114,711
FarxigaDapagliflozin Propanediol89$67,746
TradjentaLinagliptin101$66,948
VascepaIcosapent Ethyl108$42,916
EliquisApixaban27$33,940
CreonLipase/Protease/Amylase21$24,284
Icosapent Ethyl53$16,146
Combivent RespimatIpratropium/Albuterol Sulfate33$15,553
XareltoRivaroxaban13$15,042
Trelegy ElliptaFluticasone/Umeclidin/Vilanter24$14,327
Atorvastatin Calcium1,079$11,462
TrulicityDulaglutide11$10,578
Advair HfaFluticasone Propion/Salmeterol33$9,151
Losartan Potassium862$8,471

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat$125$263,412356 claims
AstraZenecaFarxiga$139$67,74689 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 13,581 internal medicine providers in California.

Other internal medicine in San Jose

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →